The main risk is sequencing, not product relevance. Vicor must convert licensing into recurring economics, hold shipments through a tight
Fab-1 period, and bring new capacity online before large customers qualify alternatives. Because the stock already embeds a scarcity premium, execution misses matter more than ordinary demand softness.